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Lipodystrophies are a heterogeneous group of human disorders characterized by the anomalous distribution
of body fat associated with insulin resistance and altered lipid metabolism. The pathogenetic mechanism of
inherited lipodystrophies is not yet clear; at the molecular level they have been linked to mutations of lamin
A/C, peroxisome proliferator-activated receptor (PPARg) and other seemingly unrelated proteins. In this
study, we examined lamin A/C processing in three laminopathies characterized by lipodystrophic pheno-
types: Dunnigan type familial partial lipodystrophy, mandibuloacral dysplasia and atypical Werner’s
syndrome. We found that the lamin A precursor was specifically accumulated in lipodystrophy cells. Pre-
lamin A was located at the nuclear envelope and co-localized with the adipocyte transcription factor sterol
regulatory element binding protein 1 (SREBP1). Using co-immunoprecipitation experiments, we obtained
the first demonstration of an in vivo interaction between SREBP1 and pre-lamin A. Binding of SREBP1 to
the lamin A precursor was detected in patient fibroblasts as well as in control fibroblasts forced to accumu-
late pre-lamin A by farnesylation inhibitors. In contrast, SREBP1 did not interact in vivo with mature lamin A
or C in cultured fibroblasts. To gain insights into the effect of pre-lamin A accumulation in adipose tissue, we
inhibited lamin A precursor processing in 3T3-L1 pre-adipocytes. Our results show that pre-lamin A seques-
ters SREBP1 at the nuclear rim, thus decreasing the pool of active SREBP1 that normally activates PPARg
and causing impairment of pre-adipocyte differentiation. This defect can be rescued by treatment with trogli-
tazone, a known PPARg ligand activating the adipogenic program.
INTRODUCTION
Lipodystrophies are a heterogeneous group of human dis-
orders characterized by the anomalous distribution of body
fat or generalized loss of adipose tissue (1). Various degrees
of insulin resistance are associated with these diseases.
Several types of lipodystrophy have been characterized at
the molecular genetic level, including Dunnigan-type familial
partial lipodystrophy (FPLD) (2), partial lipodystrophy with
mandibuloacral dysplasia (MAD) (3), syndromes of partial
lipodystrophy with cardiomyopathy (4) and Berardinelli–Seip
congenital generalized lipodystrophy (5). In FPLD and
MAD, lamin A/C mutations have been linked to disease
(2,3), whereas a form of partial lipodystrophy associated
with PPARg mutations has also been described (6). Berardi-
nelli–Seip congenital generalized lipodystrophy is due to
mutations of seipin, an endoplasmic reticulum protein (5).
Other lipodystrophies are acquired or drug-induced, such as
the lipodystrophy syndrome that is associated with the use
of highly active antiretroviral treatment (HAART) (7)
(reviewed in 1). In addition, progeroid syndromes such as
Hutchinson–Gilford progeria (HGPS) and atypical Werner’s
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syndrome (WS) show generalized lipodystrophy, often
combined with insulin resistant diabetes mellitus (8–11).
In recent years, two major players have emerged as being
possibly involved in the pathogenesis of lipodystrophies.
The first is lamin A/C, the nuclear lamina constituent
mutated in FPLD and MAD cells (2,3) as well as in progeroid
syndromes with lipodystrophy (8–11). Moreover, mutations
of ZMPSTE 24, the metalloprotease involved in lamin
A processing (12), cause diseases featuring a lipodystrophy
phenotype such as MAD in humans (13), a MAD-resembling
phenotype in knockout mice (14,15) and a HGPS
(Markquardt, personal communication).
The second emerging protein in the pathogenesis of
lipodystrophy is the sterol regulatory element binding protein
1 (SREBP1), a transcription factor whose localization and trans-
activation ability appear to be altered in acquired lipodystrophy
(7,16). In this context, it is noteworthy that mutations of PPARg
transcription factor, which is transcribed downstream of
SREBP1 activation and mediates adipocyte differentiation
(17), are responsible for other forms of partial lipodystrophy
(6,18). Moreover, a single point mutation in the PPARg
promoter has been recently associated with FPLD (19).
Lamins A and C are nuclear lamina proteins obtained by
alternative splicing of LMNA and are almost ubiquitously
expressed in differentiated tissues (20). Before being
assembled in the nuclear lamina, lamin A undergoes
complex post-translational modifications including farnesyla-
tion of the C-terminus and protease cleavage (12,13,21).
Farnesylation of pre-lamin A is necessary for the following
steps of protein cleavage, as metalloproteases fail to bind
non-farnesylated lamin A sequence (15). Mature lamin A
forms a heterodimeric complex with lamin C (22), which
appears to play structural and functional roles, not completely
elucidated (20). Lamin A/C interacts with lamin B and emerin
(23) as well as constituents of the nuclear matrix including
lamina-associated polypeptide (LAP) 2 alpha (24), nuclear
actin (25,26), transcription factor E2F and protein Rb (27).
An increasing number of LMNA mutations give rise to
several diseases grouped under the definition of laminopathies,
but characterized by different tissue-specific defects (28).
Besides the earlier-mentioned disorders affecting adipose
tissue and/or causing pre-mature aging, LMNA-linked dis-
orders include autosomal-dominant Emery–Dreifuss muscular
dystrophy (EDMD) (29), limb-girdle muscular dystrophy type
1B (30), dilated cardiomyopathy with conduction system
disease (31) affecting skeletal and/or cardiac muscle and
other diseases affecting different tissues such as Charcot–
Marie–Tooth neuropathy type 2 (32). The pathogenesis
of EDMD and other laminopathies has been extensively
investigated in recent years (33–37) and there is circumstan-
tial evidence that lamin A/C interaction with either nuclear
envelope constituents or chromatin may be affected in the
diseases (20,38–42).
SREBP/ADD1 was initially cloned from rat adipose tissue
(43) and shown to be activated in cultured fibroblasts, adipo-
cytes and liver (44,45). The human homolog of ADD1,
SREBP1, plays a major role in the control of genes involved
in adipocyte differentiation, whereas a closely related factor,
SREBP2, is mostly related to cholesterol metabolism (46).
SREBP1 is synthesized as an 125 kDa precursor and it
is embedded in the endoplasmic reticulum membrane.
Depletion of cholesterol causes proteolytic cleavage of the
transcriptionally active N-terminal portion of SREBP1 from
its position to allow translocation into the nucleus (47). A
number of published data suggest that SREBP1 interacts
with the nuclear envelope at an undefined site, while being
transferred from the endoplasmic reticulum to the nuclear
interior (48). Interestingly, SREBP1 and lamin A/C do interact
in vitro (34), suggesting that alteration of their interplay may
underlie the pathogenic mechanism of lipodystrophies. Recent
evidence shows that impairment of SREBP1 accumulation
inside the nucleus occurs in pre-adipocytes treated with an
agent employed in HAART and causative of acquired lipody-
strophy (7,16). Retention of SREBP1 at the nuclear envelope
is observed under these experimental conditions, concomitant
with anomalous accumulation of unprocessed lamin A at the
nuclear rim (7). Downstream of SREBP1 retention at the
nuclear envelope, activation of the transcription factor
PPARg, which regulates adipocyte differentiation, is impaired
(16), indicating a possible pathogenetic pathway for acquired
lipodystrophy.
In this study, we evaluated lamin A precursor maturation and
intermolecular interactions in LMNA-mutated FPLD, MAD and
WS fibroblasts and control fibroblasts. Our results show that
pre-lamin A is processed to a reduced rate in FPLD, MAD
and WS cells leading to precursor protein accumulation. Pre-
lamin A is bound to SREBP1 at the nuclear rim, thus limiting
translocation of the transcription factor to the nuclear interior.
By using 3T3-L1 pre-adipocytes as a cellular model, we also
show that forced pre-lamin A accumulation reduces the
rate of DNA-bound SREBP1 and lowers PPARg expression.
The downstream effects of reduced PPARg expression can be
rescued by troglitazone (TZD) treatment.
RESULTS
Pre-lamin A accumulates in FPLD, MAD and WS
fibroblasts
A faint pre-lamin A band was detected in control skin fibro-
blasts by western blot analysis (Fig. 1A). The amount of
lamin A precursor was increased in MAD, FPLD and WS fibro-
blasts when compared with controls (wild-type or EDMD2
fibroblasts) (Fig. 1A), whereas lamin A/C and emerin
amounts were not significantly changed (Fig. 1A). Quantitative
analysis showed a statistically significant increase in pre-lamin
A amount in MAD, FPLD and WS fibroblasts when compared
with control fibroblasts (Fig. 1B). Immunofluorescence label-
ing of pre-lamin A showed an intense nuclear rim staining in
MAD, FPLD and WS fibroblasts (Fig. 1C), whereas the precur-
sor protein was hardly detectable in wild-type cells (Fig. 1C).
Moreover, a faint pre-lamin A staining was detected at the
nuclear rim of R401C-mutated EDMD2 cells (Fig. 1C) and in
other EDMD2 cell lines bearing five different LMNA mutations
(data not shown). Intra-nuclear pre-lamin A-labeled structures
were observed in MAD, FPLD and WS fibroblasts (Fig. 1C,
arrowheads). Mis-localization of pre-lamin A to intra-nuclear
structures was observed in a percentage of EDMD2 cells
(Fig. 1C) (data not shown). Emerin co-localized with pre-
lamin A at the nuclear rim, whereas pre-lamin A-labeled
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intra-nuclear structures did not co-localize with emerin in
lipodystrophy nuclei (Fig. 1C).
To check whether farnesylation of lamin A precursor was an
ongoing process in the examined cell lines, we performed
mevinolin treatment (21). Accumulation of unprocessed
lamin A was observed after mevinolin treatment in all exam-
ined cell lines (compare Fig. 2A with Fig. 1A), but a higher
pre-lamin A amount was detected in FPLD, MAD and WS
fibroblasts by western immunoblot (compare Fig. 2A with
Fig. 1A). Mature lamin A band was slightly reduced in
mevinolin-treated samples, whereas lamin C and emerin
expressions were not or slightly affected by mevinolin
administration (compare Fig. 2A with Fig. 1A). Densitometric
analysis of pre-lamin A immunoblotted bands showed an
increase in each mevinolin-treated control and laminopathic
cell line when compared with its corresponding untreated
cell line (Fig. 2B). In wild-type fibroblasts forced to accumu-
late pre-lamin A, nuclear lamina invaginations were observed
(Fig. 2C and C0, arrowheads): pre-lamin A-labeled structures
were detected in the equatorial plane of the nucleus
(Fig. 2C0), starting from the nuclear rim (Fig. 2C0). Nuclear
lamina invaginations were also observed in MAD and WS
fibroblasts (Fig. 2C, arrowheads), whereas FPLD nuclei
showed anomalous pre-lamin A aggregates localized at the
Figure 1. Analysis of pre-lamin A expression and localization in control and laminopathic fibroblasts. (A) Western blot analysis of pre-lamin A in untreated skin
fibroblasts. Whole cell lysates from control (C), MAD, FPLD, WS and EDMD2 fibroblasts were submitted to electrophoresis, western blotted and probed using
anti-pre-lamin A antibody. Immunoblotted membranes were stripped and re-probed with anti-lamin A/C, anti-emerin or anti-actin antibodies (lower panels).
Actin staining shows equal loading of samples. Molecular weight markers are reported in kilodalton. (B) Densitometric analysis of pre-lamin A immunoblotted
bands shown in panel (A). Immunoblotted bands were quantified by densitometry. At least three independent experiments were performed for western immunoblot
analysis of pre-lamin A accumulation, equal loading of samples was checked using actin as an internal loading control and data were calculated as percentage of
control pre-lamin A densitometry obtained in each experiment. Values are reported as a percentage of control pre-lamin A amount (mean+ SEM of three different
experiments). Densitometric values obtained for untreated MAD, FPLD and WS samples are significantly different from control values, as calculated by Student’s
t-test (P, 0.05). (C) Localization of pre-lamin A in control, MAD, FPLD, WS and EDMD2 fibroblasts. Double-staining of pre-lamin A and emerin was performed by
anti-pre-lamin A polyclonal antibody (Santa Cruz, SC-6214, revealed by FITC-conjugated secondary antibody) and anti-emerin monoclonal antibody (revealed by
Cy-3-conjugated secondary antibody). Pictures were obtained by fluorescence microscopy. Pre-lamin A-labeled intra-nuclear structures are marked by arrowheads.
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nuclear rim (Fig. 2C) (data not shown) (42). In mevinolin-treated
wild-type fibroblasts, pre-lamin A-labeled intra-nuclear struc-
tures partially co-localized with emerin, whereas they did not
co-localize with emerin in MAD, FPLD or WS nuclei (Fig. 2C).
SREBP1 is bound to pre-lamin A in vivo
SREBP1 was detected in control and laminopathic fibroblasts
as an 125 kDa precursor and as an active cleaved form
(68 kDa) (Fig. 3A). An additional low molecular weight band
was observed in mevinolin-treated controls and in FPLD,
MAD and WS fibroblasts (Fig. 3A). In vivo binding of pre-
lamin A to the active 68 kDa SREBP1 form was detected in
control human fibroblasts following mevinolin-treatment
(Fig. 3A) and in FPLD, MAD and WS fibroblasts either
untreated (Fig. 3A) or after mevinolin administration (data
not shown). Co-precipitation of SREBP1 and pre-lamin A
was observed using either anti-pre-lamin A or anti-SREBP1
antibody to immunoprecipitate protein complexes (Fig. 3A).
In contrast, we failed to co-immunoprecipitate lamin A/C
using anti-SREBP1 antibody (Fig. 3A). Moreover, lamin
A/C was not co-precipitated by anti-pre-lamin A antibody
(Fig. 3A). An emerin immunoprecipitation was performed as
a control, which showed absence of co-precipitation of
SREBP1 (Fig. 3A). These results were confirmed by immuno-
precipitation experiments using anti-lamin A/C antibody
(Fig. 3B). SREBP1 was not detected in the protein complex
precipitated by anti-lamin A/C antibody (Fig. 3B). It should
be noted that only in fibroblasts expressing high pre-lamin
A levels, cross-reactivity of anti-lamin A/C antibody with
pre-lamin A caused immunoprecipitation of pre-lamin A (and
co-precipitation of a proportional amount of SREBP1) by
Figure 2. Analysis of pre-lamin A expression and localization in mevinolin-treated control and laminopathic fibroblasts. (A) Western blot analysis of pre-lamin
A in skin fibroblasts, following 18 h mevinolin treatment. Whole cell lysates from control (C), MAD, FPLD, WS and EDMD2 fibroblasts were submitted to
electrophoresis, western blotted and probed using anti-pre-lamin A antibody. Immunoblotted membranes were stripped and re-probed with anti-lamin A/C,
anti-emerin or anti-actin antibodies (lower panels). Actin staining shows equal loading of samples. Molecular weight markers are reported in kilodaltons.
(B) Densitometric analysis of pre-lamin A immunoblotted bands shown in panel (A). Immunoblotted bands were quantified by densitometry. At least three inde-
pendent experiments were performed for western immunoblot analysis of pre-lamin A accumulation. Equal loading of samples was checked using actin as an
internal loading control and data were calculated as percentage of pre-lamin A densitometry measured in each untreated cell line. Values are reported as a per-
centage of pre-lamin A amount in each corresponding untreated cell line (Fig. 1A and B) and they represent means+ SEM of three different experiments.
Western blotting of untreated fibroblasts (Fig. 1A) and mevinolin-treated fibroblasts (A) was routinely performed on the same membrane to allow comparison
of results. (C) Localization of pre-lamin A in mevinolin-treated control, MAD, FPLD and WS fibroblasts. Double-staining of pre-lamin A and emerin was
performed by anti-pre-lamin A polyclonal antibody (Santa Cruz, SC-6214, revealed by FITC-conjugated secondary antibody) and anti-emerin monoclonal anti-
body (revealed by Cy-3-conjugated secondary antibody (C0) Localization of pre-lamin A in mevinolin-treated wild-type nuclei (control). Pictures were obtained
at two different focal planes (lamina plane, equatorial plane). Pre-lamin A-labeled intra-nuclear structures shown in (C) and (C0) are marked by arrowheads.
Pictures were obtained by fluorescence microscopy.
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anti-lamin A/C antibody (Fig. 3B). Figure 3C shows immuno-
fluorescence labeling of SREBP1 in wild-type, MAD, FPLD,
WS and EDMD2 fibroblasts. The transcription factor was loca-
lized inside the nucleus of control fibroblasts (wild-type and
R401C EDMD2 fibroblasts) and a faint cytoplasmic labeling
was observed (Fig. 3C). In MAD, FPLD and WS fibroblasts,
nuclear rim staining was also observed (Fig. 3C).
Pre-lamin A accumulation in 3T3-L1 pre-adipocytes
causes SREBP1 retention at the nuclear rim
In differentiating 3T3-L1 pre-adipocytes, a sharp SREBP1
68 kDa band was detected by western blot analysis, while
the 125 kDa precursor protein was less intensely stained
(Fig. 4A). Mevinolin treatment caused accumulation of pre-
lamin A, whereas SREBP1 level was not affected (Fig. 4A,
lanes 1 and 2).
A stable interaction between SREBP1 and pre-lamin A was
detected by co-immunoprecipitation assay in differentiating
3T3-L1 adipocytes induced to accumulate unprocessed lamin
A (Fig. 4A). This result was obtained using either anti-pre-
lamin A or anti-SREBP1 antibody to co-precipitate protein
complexes (Fig. 4A, lanes 3–6). Even in differentiating
3T3-L1 adipocytes, we failed to detect SREBP1-lamin A/C
binding (Fig. 4A, lanes 3–8).
To investigate the role of SREBP1–pre-lamin A interaction,
we first checked the sub-cellular distribution of SREBP1 in
3T3-L1 pre-adipocytes, accumulating or not pre-lamin
Figure 3. Detection of SREBP1–pre-lamin A binding in human fibroblasts. (A). Western blot analysis of whole lysates from control (lane 1), mevinolin-treated
control (lane 2), MAD (lane 3), FPLD (lane 4) and WS fibroblasts (lane 5) is shown in the left panel (whole lysate). Untreated or mevinolin-treated control
fibroblasts and untreated FPLD, MAD and WS fibroblast lysates were subjected to immunoprecipitation using anti-pre-lamin A (pre-A IP) or anti-SREBP1 anti-
body (SREBP1 IP). Co-immunoprecipitated proteins were separated by electrophoresis, western blotted and probed with anti-pre-lamin A and anti-SREBP1 and
anti-lamin A/C antibodies. Anti-emerin antibody was used to immunoprecipitate protein complexes, as a specificity control (emerin IP). Active SREBP1 is
detected as a 68 kDa band, the uncleaved protein as an 125 kDa band. An additional SREBP1 band below 68 kDa is observed in cellular lysates accumulating
pre-lamin A. (B) Untreated (lane 1) or mevinolin-treated (lane 2) control fibroblasts and untreated MAD (lane 3), FPLD (lane 4) and WS fibroblast lysates (lane
5) were subjected to immunoprecipitation using anti-lamin A/C antibody (lamin A/C IP). Co-immunoprecipitated proteins were separated by electrophoresis,
western blotted and probed with anti-lamin A/C and anti-SREBP1 antibody. Protein A/G panels (A/G) show the absence of non-specific binding when
primary antibody is omitted in the immunoprecipitation mixture. Asterisks in panel A and B mark pre-lamin A band detected by anti-lamin A/C antibody. Mol-
ecular weight markers are reported in kilodaltons. (C) Localization of SREBP1 in wild-type, MAD, FPLD, WS and EDMD2 fibroblasts. SREBP1 is labeled by
anti-SREBP1 antibody and it is detected by FITC-conjugated secondary antibody. Pictures are obtained by fluorescence microscopy.
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A. Faint SREBP1 bands were detected in the cytoplasmic frac-
tions (Fig. 4B, lanes 1 and 5), whereas the 68 kDa cleaved
protein only was recovered in the nuclear fractions (Fig. 4B,
lanes 2–4 and 6–8). In untreated nuclei, the 68 kDa active
SREBP1 form was almost completely solubilized after
DNase treatment (Fig. 4B, lane 3), whereas SREBP1 band
was hardly detectable in the insoluble nuclear fraction
(Fig. 4B, lane 4). In contrast, in mevinolin-treated nuclei,
active SREBP1 band was clearly detected both in the DNase
soluble fraction (Fig. 4B, lane 7) and in the insoluble
nuclear fraction (Fig. 4B, lane 8). As expected, pre-lamin A
was recovered in purified nuclei from mevinolin-treated cells
(Fig. 4B, lane 6) and it was almost completely retained in
the insoluble nuclear fraction after DNase extraction
(Fig. 4B, lane 8). Densitometric analysis showed that the
amount of activated SREBP1 recovered in the insoluble
nuclear fraction was significantly increased in 3T3-L1 pre-adi-
pocytes accumulating pre-lamin A (Fig. 4C).
SREBP1 is retained at the nuclear rim of cells
accumulating pre-lamin A
Double immunofluorescence staining of SREBP1 and pre-
lamin A was performed (Fig. 5). In untreated 3T3-L1
Figure 4. SREBP1–pre-lamin A interaction in 3T3-L1 pre-adipocytes. (A) Detection of SREBP1–pre-lamin A binding in 3T3-L1 pre-adipocytes. Cellular
lysates from 3T3-L1 cells (treated or not with mevinolin) were subjected to immunoprecipitation using anti-pre-lamin A (pre-A IP, lanes 3 and 4), anti-
SREBP1 (SREBP1 IP, lanes 5 and 6) or anti-lamin A/C antibody (A/C IP, lanes 7 and 8). Co-precipitated proteins were separated by electrophoresis,
western blotted and probed with anti-pre-lamin A and anti-SREBP1 antibodies. Western blot analysis of the whole cellular lysate (WL) used as input is
shown in lanes 1 and 2. Active SREBP1 is detected as a 68 kDa band, the uncleaved protein as an 125 kDa band (middle). Stripped membranes were re-
probed with anti-lamin A/C antibody. Asterisk in the lower panel shows pre-lamin A band detected by anti-lamin A/C antibody. Protein A/G panel (A/G)
shows the absence of non-specific binding when primary antibody is omitted in the immunoprecipitation mixture (lanes 9 and 10). Molecular weight
markers are reported in kilodaltons. (B) Biochemical analysis of the sub-cellular distribution of SREBP1 and pre-lamin A in untreated or mevinolin-treated
3T3-L1 pre-adipocytes. Cell pellets were resuspended in a lysis buffer containing 10 mM Tris pH 7.8, 1% NP-40, 10 mM 2-mercaptoethanol and protease inhibi-
tors. Separation of nuclei (N) was obtained by hypotonic shock and shearing: DNase extraction of nuclei was performed using 100 U/ml of DNase; soluble
fraction (DNase) and nuclear matrix proteins (NP) were separated by centrifugation. Each sub-cellular fraction was resuspended in sample buffer, subjected
to electrophoresis and western blot and probed with anti-pre-lamin A and anti-SREBP1 antibodies. Stripped membranes were re-probed with anti-emerin anti-
body as a loading control. Lanes 1 and 5 represent cytosolic fractions (C); lanes 2 and 6 represent purified nuclei (N); lanes 3 and 7 represent DNase soluble
nuclear fractions (DNase) and lanes 4 and 8 represent insoluble nuclear fractions (NP). Molecular weight markers are reported in kilodaltons. (C) Densitometric
analysis of 68 kDa SREBP1 immunoblotted bands shown in panel (B). Immunoblotted bands were quantified by densitometry. Values are reported as a percen-
tage of 68 kDa SREBP1 band detected in each corresponding untreated adipocyte fraction (mean+ SEM of three different experiments). Western blotting of
untreated fibroblast fractions (B, untreated) and mevinolin-treated fibroblast fractions (B, mevinolin-treated) was routinely performed on the same membrane to
allow comparison of results.
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pre-adipocytes (Fig. 5A), SREBP1 localized inside the
nucleus (Fig. 5A). In mevinolin-treated 3T3-L1 pre-
adipocytes, co-localization of SREBP1 and pre-lamin A at
the nuclear rim was observed (Fig. 5A). In untreated nuclei
from control fibroblasts (wild-type or EDMD2 fibroblasts),
SREBP1 localized at the nuclear interior, whereas the tran-
scription factor was also observed at the nuclear rim of
MAD and FPLD fibroblasts (Fig. 5B). To support the
evidence of SREBP1 retention in the nuclear insoluble
fraction by pre-lamin A, in situ-DNase extraction was per-
formed. Following DNase-digestion, SREBP1 was hardly
detectable in the nuclei of 3T3-L1 cells which did not
undergo mevinolin treatment, yet it was retained at the
nuclear rim of mevinolin-treated pre-adipocytes, where it co-
localized with pre-lamin A (Fig. 5C). SREBP1 labeling
was almost undetectable in wild-type and EDMD2 fibroblasts
following DNase treatment, whereas it was observed at the
nuclear rim of DNase-extracted MAD and FPLD fibroblasts
(Fig. 5D).
Pre-lamin A accumulation reduces PPARg levels in
3T3-L1 nuclei and impairs adipocyte differentiation:
rescue by TZD treatment
Since the transcription factor PPARg is transcribed following
SREBP1 activation in pre-adipocytes induced to differentiate
(7,17), we checked PPARg levels in differentiating 3T3-L1
cells accumulating pre-lamin A. To rule out the possibility
that mevinolin could interfere with cholesterol synthesis by
inhibiting HMG-CoA reductase, pre-lamin A accumulation
was also obtained using the farnesyltransferase inhibitor
FTI-277 or by transfecting cell cultures with an uncleavable
pre-lamin A mutant (as described subsequently). PPARg
expression was strongly reduced in mevinolin-treated 3T3-
L1 pre-adipocytes, as determined by western blot (Fig. 6A)
and immunofluorescence analysis (Fig. 6B). Downregulation
of PPARg was also obtained using FTI-277 to accumulate
pre-lamin A (data not shown). To support this observation,
we transiently transfected 3T3-L1 pre-adipocytes with
Figure 5. Localization of SREBP1 in the nuclei accumulating pre-lamin A. Cells were double-stained with anti-SREBP1 and anti-pre-lamin A antibody.
SREBP1 is detected by FITC-conjugated secondary antibody (green) and pre-lamin A is detected by Cy-3 conjugated secondary antibody (red). (A) Localization
of SREBP1 and pre-lamin A in untreated (3T3) or mevinolin-treated 3T3-L1 pre-adipocytes (3T3mev). (B) Double-immunofluorescence staining of SREBP1 and
pre-lamin A in wild-type (control), MAD, FPLD and EDMD2 fibroblasts. (C) Localization of SREBP1 and pre-lamin A in untreated (3T3) or mevinolin-treated
3T3-L1 pre-adipocytes (3T3mev), following in situ extraction with DNase. DNase extraction of unfixed adherent cells was performed using 20 U/ml of DNase
for 15 min at room temperature. Cells were double-stained as described earlier. (D) Double-immunofluorescence staining of SREBP1 and pre-lamin A in wild-
type (control), MAD, FPLD and EDMD2 fibroblasts following DNase extraction. The merged images (merge) show yellow staining of the nuclear envelope in
fibroblasts accumulating SREBP1 and pre-lamin A at the nuclear rim. The reported results are representative of three independent experiments.
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a FLAG-tagged lamin A construct overexpressing an unclea-
vable L648R mutated pre-lamin A: PPARg was downregu-
lated in the nuclei accumulating FLAG–L648R pre-lamin A
(Fig. 6B and C). Overexpression of wild-type FLAG–lamin
A (FLAG–LA) was also effective in reducing PPARg level
(Fig. 6B and C), whereas PPARg expression was not
lowered in 3T3-L1 cells overexpressing the full-length
emerin protein, here used as a control (Fig. 6B and C). Statisti-
cal evaluation of these results showed that the percentage of
PPARg-labeled nuclei was significantly reduced in cells
accumulating pre-lamin A (Fig. 6C). It should be noted that
the 74 kDa pre-lamin A band only was detected in FLAG–
L648R pre-lamin A-transfected cells by western immunoblot
(Fig. 6D). On the other hand, accumulation of wild-type pre-
lamin A along with mature lamin A occurred in pre-adipocytes
overexpressing FLAG–LA (Fig. 6D).
Accumulation of pre-lamin A reduced adipocyte differen-
tiation, as detected by oil red O staining of mevinolin- or
FTI-277-treated 3T3-L1 cultures (Fig. 6E). However, 3T3-
L1 cells treated with the PPARg ligand TZD showed positive
oil red O staining even after accumulation of pre-lamin A by
mevinolin or by FTI-277 treatment (Fig. 6E), indicating the
rescue of adipogenic differentiation.
DISCUSSION
The results reported here show that (i) accumulation of pre-
lamin A specifically occurs in lipodystrophy-linked laminopa-
thies, but not in EDMD2; (ii) in vivo binding of pre-lamin A to
the adipocyte transcription factor SREBP1 does occur and it is
detectable in cells accumulating pre-lamin A; (iii) pre-lamin A
sequesters SREBP1 at the nuclear rim, thus reducing the pool
of DNA-bound active transcription factor; (iv) retention of
SREBP1 by pre-lamin A causes downregulation of PPARg
expression and hence reduces the rate of pre-adipocyte differ-
entiation and (v) adipogenic differentiation of pre-adipocytes
accumulating pre-lamin A may be rescued by PPARg ago-
nists. The overall evaluation of these results shows that a
common pathogenic mechanism may be causative of different
lipodystrophic phenotypes.
The proposed mechanism involves primarily in the accumu-
lation of pre-lamin A and selective binding of the lamin A pre-
cursor to the adipocyte transcription factor SREBP1. In MAD,
FPLD and WS cells, we observed an accumulation of the
lamin A precursor. Interestingly, the amount of pre-lamin A
was not increased in EDMD2 fibroblast cell lines, indicating
that impairment of lamin A precursor maturation is specifi-
cally associated with lipodystrophy-linked lamin A mutations.
However, the reason why lamin A processing is selectively
affected by R482L, R527H and S143F LMNA mutations is
not obvious. At present, we can rule out the possibility of
altered interplay between pre-lamin A and farnesyltrans-
ferases. In fact, mevinolin treatment was effective in increas-
ing mutated pre-lamin A amount in MAD, FPLD and WS
fibroblasts, suggesting that farnesylation of pre-lamin A is
an ongoing mechanism in these cells (MAD being a recessive
disease model, only expressing mutated lamin A). On the
other hand, altered interaction of mutated pre-lamin A with
ZPMSTE 24 endoprotease might affect protein processing. It
is noteworthy that ZPMSTE 24 mutations lead to accumu-
lation of pre-lamin A due to impaired cleavage of the farnesy-
lated protein and cause MAD (13), HGPS (Markquardt,
personal communication) and restrictive dermopathy (49) in
humans and a MAD-resembling phenotype in mice (14,15).
We localized pre-lamin A-labeled intra-nuclear structures
both in wild-type and in laminopathic cells accumulating the
lamin A precursor. Such structures have been previously
shown in wild-type cells induced to accumulate pre-lamin A
(21,50). However, additional dominant negative effects of
mutations appear to affect differently both number and shape
of pre-lamin A-labeled structures in each laminopathic cell
line. In the case of MAD and WS fibroblasts, pre-lamin-A-
containing structures mostly protrude through the nuclear
interior, as was also observed in control nuclei, whereas in
R482L FPLD nuclei they are mostly localized at the nuclear
lamina level. We recently noticed that the number of pre-
lamin-A-labeled intra-nuclear structures and the level of
lamin A precursor were significantly increased in older
MAD patients, though carrying the same R527H LMNA
mutation (data not shown). Noticeably, pre-lamin A-labeled
structures may co-localize with emerin in wild-type and
Figure 6. Analysis of PPARg expression and adipocyte differentiation in 3T3-L1 pre-adipocytes accumulating pre-lamin A. (A) 3T3-L1 pre-adipocytes were left
untreated (c) or treated with mevinolin for 18 h (mev), thereafter allowed to differentiate for 4 days in differentiation medium. Nuclear lysates were obtained by
hypotonic shock and shearing and subjected to electrophoresis and western blot analysis with anti-PPARg and anti-pre-lamin A antibody. Immunoblotted mem-
branes were stripped and re-probed with anti-SREBP1 and anti-emerin antibody. The 68 kDa SREBP1 band was detected in the nuclear fractions. Emerin was
labeled as a loading control. Molecular weight markers are reported in kilodaltons. (B) 3T3-L1 pre-adipocytes grown on coverslips were treated with mevinolin
or transfected with the indicated constructs and allowed to differentiate for 4 days. Double-immunofluorescence staining of pre-lamin A and PPARg was per-
formed in mevinolin-treated samples (mevinolin). Double-staining with anti-FLAG and anti-PPARg antibodies was performed in FLAG–LA-transfected pre-
adipocytes (FLAG–LA), L648R-lamin A-transfected adipocytes (FLAG–L648R) and emerin-transfected adipocytes (FLAG–emerin). DAPI staining allows
visualization of all the nuclei. (C) Percentage of PPARg-positive nuclei in 3T3-L1 pre-adipocytes subjected to mevinolin treatment (mevinolin-treated), over-
expressing wild-type FLAG–LA, mutated L648R FLAG–LA (FLAG–L648R) or FLAG–emerin. One-thousand nuclei were counted per sample and data are
reported as percentage of counted nuclei (+SEM) of three separate countings performed in independent experiments. (D) Western blot analysis of exogenous
proteins expressed in 3T3-L1 cells (FLAG–LA, FLAG-tagged wild-type lamin A; FLAG–L648R, FLAG-tagged L648R-mutated lamin A; FLAG–emerin,
FLAG-tagged wild-type emerin). Each construct was transfected in 3T3-L1 cells. Cellular lysates were subjected to western immunoblot using anti-FLAG anti-
body. The 74 kDa band corresponds to FLAG–pre-lamin A, the 70 kDa band corresponds to FLAG–LA, the 34 kDa band corresponds to FLAG–emerin. (E)
Pre-adipocyte differentiation was evaluated by oil red O staining of cultured 3T3-L1 cells on day 2 of differentiation. 3T3-L1 cultures were left untreated
(control) or treated with mevinolin for 18 h or with FTI-277 for 24 h. Thereafter, cells were allowed to differentiate for 2 days either in the presence or in
the absence of 10 mM TZD. An untreated culture (control) is shown on the left of each slide, a drug-treated culture (mevinolin or FTI-277) is shown in the
middle and a culture treated with mevinolin or FTI-277 and then with TZD for further 48 h (mevinolin þ TZD or FTI-277 þ TZD) is shown on the right.
Oil red O staining is increased in differentiated cells bearing fat deposits. Pre-lamin A staining of representative nuclei from each 3T3-L1 sample is shown
in the lower row (pre-lamin A). Each of these pictures is representative of three independent experiments.
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EDMD2 nuclei, but not in FPLD, MAD and WS nuclei,
suggesting disease-specific changes of intermolecular inter-
actions (42).
Because we had determined a link between pre-lamin A
accumulation and LMNA-associated lipodystrophies, we
decided to investigate whether pre-lamin A interacted with
the transcription factor SREBP1, which mediates adipocyte
differentiation (44). In vitro binding of SREBP1 to lamin A/
C had been demonstrated by Lloyd et al. (34) and the site of
interaction had been mapped between aminoacids 227 and
487 of SREBP1 N-terminus sequence (34). In the present
study, we demonstrated for the first time in vivo binding of
the lamin A precursor to SREBP1. As expected, the low-
molecular-weight form of SREBP1 interacts with pre-lamin
A, indicating involvement of the nuclear lamina protein in
the localization of the active transcription factor. Interestingly,
Lloyd et al. (34) performed a GST binding-assay with a lamin
A peptide spanning aminoacids 389–664, which includes pre-
lamin A C-terminal sequence. Thus, our results confirm that
the whole unprocessed lamin A molecule is required for
SREBP1 interaction in vivo. The previously suggested
reduction of lamin A–SREBP1 binding affinity caused by
R482 LMNA mutation (34) does not appear to affect in vivo
interaction between pre-lamin A and SREBP1. This might
be related to the increased availability of pre-lamin A in
FPLD cells, which could overcome the reduced binding affi-
nity caused by the mutation. In addition, we cannot rule out
the possibility that a different aminoacid substitution (R482L
instead of R482W) may differently affect protein interplay
(42).
By treating pre-adipocytes with farnesylation inhibitors, we
obtained a suitable cellular model that reproduced the situation
of pre-lamin A accumulation in adipose tissue. This allowed
us to investigate some biological mechanisms downstream
of reduced pre-lamin A maturation.
We showed that the retention of active SREBP1 at the
nuclear lamina occurs in pre-adipocytes accumulating
pre-lamin A, as demonstrated by the significantly increased
proportion of mature SREBP1 found in the nuclear insoluble
fraction following DNase extraction. Immunofluorescence
labeling allowed us to show co-localization of SREBP1 and
pre-lamin A in the nuclei accumulating pre-lamin A. In fact,
DNA-bound transcription factor disappears from control
nuclei after the removal of DNA, whereas lamina-associated
SREBP1 is still retained in the nuclei accumulating pre-
lamin A and shows a typical nuclear rim staining. We
suggest that the reduced rate of lamin A precursor processing
allows detection of pre-lamin A-bound SREBP1, which is
hardly detectable in control cell lines undergoing rapid pre-
lamin A maturation.
It is noteworthy that SREBP1 nuclear translocation is
impaired in Lmna-null mouse cardiomyocytes, but not in the
adipose tissue from Lmna null mice (36), indicating that
nuclear import of SREBP1 in adipocytes does not require
Lmna products. These data and our present results support
the view that SREBP1–pre-lamin A interplay has a physio-
logical role in the negative regulation of SREBP1 nuclear
translocation in adipose tissue, so that excess accumulation
of pre-lamin A selectively sequesters SREBP1 at the adipo-
cyte nuclear envelope. On the other hand, pre-lamin A
might play a positive regulation role for SREBP1 nuclear
import in other cell types such as cardiac myocytes (36). In
agreement with this hypothesis, pre-lamin A–SREBP1 inter-
play, which is potentially disrupted by some LMNA mutations
causing AD-EDMD (34), might be involved in the nuclear
import of the transcription factor in skeletal muscle cells.
Retention of SREBP1 at the nuclear rim was previously
reported in 3T3-F442A pre-adipocytes treated with Indinavir,
a drug employed in HAART and causing lipodystrophy as a
side-effect (7). Under these experimental conditions, 3T3-
F442A fibroblasts show increased pre-lamin A level and
reduced PPARg expression (7). These and our results strongly
suggest that retention of SREBP1 at the nuclear rim of lipody-
strophy cells is associated with the presence of increased pre-
lamin A level, irrespective of the occurrence of LMNA
mutations. In fact, the identification of a selective and stable
interplay between pre-lamin A and SREBP1 helps to explain
the pathophysiology of both acquired and inherited lipodystro-
phy, the latter due to either lamin A/C or ZMPSTE 24
mutations. Moreover, it is noteworthy that farnesyltransferase
inhibitors (causing pre-lamin A accumulation) have been pre-
viously reported to impair adipocyte differentiation (51,52).
Our results help in explaining the biological mechanism
underlying this effect.
A key event of adipocyte differentiation is the induction of
the transcription factor PPARg which is triggered by SREBP1
(48). Downregulation of PPARg expression was obtained in
pre-adipocytes accumulating the lamin A precursor either by
mevinolin treatment or by overexpressing uncleavable pre-
lamin A. Uncleavable mutants of lamin A have been shown
to assemble and localize at the nuclear envelope with kinetics
comparable with that of wild-type protein (53). The L648R-
lamin A mutant did in fact localize at the nuclear envelope,
where it could potentially bind SREBP1, as observed for de-
farnesylated pre-lamin A. Interestingly, a reduced PPARg
level was also observed in adipocytes accumulating wild-
type FLAG–pre-lamin A. In the latter case, the increase of
pre-lamin A level was directly attributable to overexpression
of the exogenous protein. These results support the view that
excess accumulation of pre-lamin A is sufficient to sequester
an amount of SREBP1, even in the presence of mature
lamin A. Thus, PPARg induction, a key step of adipocyte
differentiation, may be altered in laminopathies featuring lipo-
dystrophy, as already proposed for acquired lipodystrophies
(7,16).
In fact, adipocyte differentiation was impaired by pre-lamin
A accumulation, as determined by oil red O staining of mevi-
nolin- or FTI-277-treated pre-adipocyte cultures. Given that
FTI-277 selectively affects pre-lamin A processing without
any interference with ras protein farnesylation or with choles-
terol synthesis (54), we conclude that reduced adipocyte
differentiation is a direct effect of pre-lamin A accumulation.
It should be noted that highly differentiated cultures were not
affected by drug treatment (data not shown), in agreement
with the evidence that an early event in the adipocyte differen-
tiation pathway, such as PPARg activation, is affected by pre-
lamin A.
PPARg expression has been reported to be regulated depen-
dent on the body district (55). This important observation
suggests that pre-lamin A accumulation may elicit different
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effects in different fat depots depending on the extent of
PPARg activation required in that particular area. This
could, in part, explain the selective involvement of some but
not all adipose tissue districts in partial lipodystrophies.
Treatment of 3T3-L1 cells accumulating pre-lamin A with
the PPARg ligand TZD elicited rescue of the adipogenic
program. The latter finding gives an important insight into
possible therapeutic approaches to lipodystrophy, which
have been already reported to elicit some promising effects
(56).
As MAD is a recessive disease, one would expect pre-lamin
A accumulation even in the heterozygous state, i.e. in a per-
centage of cells from parents of affected individuals bearing
one mutated allele (3). We did not observe a significant
increase of pre-lamin A amount in those cells. However, this
study deserves further deepening, since we found that overex-
pression of R527H-mutated lamin A in transfected cells causes
accumulation of mutated pre-lamin A (but not endogenous
pre-lamin A) (data not shown). On the other hand, MAD phe-
notype is not observed in heterozygous individuals, strongly
supporting the view that a threshold pre-lamin A level is
required to activate the pathogenic mechanism. Regarding
the pathophysiology of MAD and WS, two main questions
need further investigation. The first is the effect elicited by
the accumulation of lamin A precursor protein in osteoblasts.
In fact, bone resorption of the extremities is a specific feature
of MAD phenotype (3) and osteoporosis is also observed in
WS patients (11) (though it might be related to the aging
process featuring this disease). We are now addressing this
problem by evaluating the effect of high pre-lamin A level
in pre-osteocyte differentiation or survival. The other open
question is the pathogenetic mechanism leading to a premature
aging phenotype in MAD patients and mostly in WS patients.
We suggest that this phenotype could be dependent both on an
anomalous amount of pre-lamin A and on altered interaction
between mutated lamin A/C and its nuclear binding partners.
MATERIALS AND METHODS
Cell culture and differentiation
Skin biopsies were obtained from a MAD patient carrying an
R527H lamin A/C mutation (3), an FPLD patient carrying
an R482L lamin A/C mutation (42), an atypical WS patient
carrying an S143F LMNA mutation, an EDMD2 patient carry-
ing R401C LMNA mutation and from unaffected controls fol-
lowing their written consent. Fibroblast cultures were
established and cultured in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum
(FCS) and antibiotics. Cells at passages 10–15 were
employed. 3T3-L1 pre-adipocytes were obtained from the
European Collection of Cell Cultures and cultured in
DMEM plus 10% FCS. Pre-adipocytes approaching conflu-
ence were induced to differentiate by incubation for 2 days
in a differentiation medium containing DMEM plus 10%
FCS, 5 mg/ml insulin, 0.25 mM dexamethasone and 0.1 mM
3-isobutyl-1-methylxanthine. Thereafter, incubation was per-
formed for an additional 2 days in the same medium excluding
dexamethasone and 3-isobutyl-1-methylxanthine. Cells were
maintained for 8–10 days in DMEM with 10% FCS to
attain maximal differentiation (57).
Transfection of pre-adipocyte cultures
A full-length rat lamin A cDNA encoding for pre-lamin A was
expressed from the CMV promoter and tagged at the 50 end
with a sequence coding for FLAG epitope (FLAG–LA)
(58). The L648R point mutation was introduced into the
full-length rat lamin A cDNA using the QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA, USA).
This mutation impairs cleavage of pre-lamin A by
ZMPSTE24 endoprotease and causes accumulation of farnesy-
lated pre-lamin A (12). FLAG–LA or L648R–FLAG-lamin A
was transfected in 3T3-L1 pre-adipocytes at day 0 of differen-
tiation. A FLAG-tagged wild-type emerin construct was used
to transfect pre-adipocytes as a control. Transfection of 3T3-
L1 pre-adipocytes was performed using FuGene 6 reagent
according to the manufacturer’s instructions. Cells were
fixed at day 4 of differentiation.
Drug treatments
Pre-lamin A accumulation in human fibroblasts and 3T3-L1
adipocytes was induced by inhibition of isoprenoid synthesis
with 25 mM Mevinolin (Sigma) for 18 h (21). This drug sub-
tracts the substrate of farnesyltransferases, thus impairing
pre-lamin A farnesylation which is required for further
protein processing (59). Alternatively, pre-lamin A farnesyla-
tion was inhibited using the peptidomimetic drug FTI-277
(Calbiochem), which selectively impairs pre-lamin A farnesy-
lation, at the dosage used (20 mM for 24 h) (54). Treatment
with TZD (Sigma) was performed according to the published
protocols to trigger PPARg activation (16). Briefly, 3T3-L1
pre-adipocytes were induced to accumulate pre-lamin A by
18 h mevinolin treatment or by 24 h FTI-277 treatment. There-
after, cells were transferred in culture medium, containing or
not 10 mM TZD, and incubated for 48 h. Incubation was
stopped by formalin fixation, as described subsequently.
Sub-cellular fractioning and DNase treatment
Sub-cellular fractions were obtained as previously described
(26). Briefly, the cell pellet was resuspended in a lysis
buffer containing 10 mM Tris, pH 7.8, 1% NP-40, 10 mM
2-mercaptoethanol and protease inhibitors. Separation of
nuclei was obtained by hypotonic shock and shearing; nuclei
were obtained as pellet by a 300g centrifugation at 48C.
Other samples were treated by the same procedure and
employed to obtain the cytoplasmic fraction as supernatant.
Cytoplasmic fractions were clarified by centrifugation at
600g. DNase extraction of nuclei was performed according
to published protocols (42) except that 100 U/ml of DNase
was applied for 30 min. The insoluble nuclear fraction (NP
in Fig. 4), containing nuclear matrix constituents, was
obtained as pellet. Each fraction was then resuspended in
loading buffer, subjected to sodium dodecyl sulphate–poly-
acrylamide gel electrophoresis (SDS–PAGE) and western
blot analysis.
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In situ DNase extraction was performed as follows. Unfixed
cell cultures were washed in phosphate-buffered saline (PBS),
treated with a buffer containing 10 mM Tris-HCl (pH 7.4),
150 mM NaCl, 5 mM MgCl2, 1% NP-40, 1 mM phenylmethyl-
sulfonyl fluoride (PMSF), 10 mg/ml leupeptin and aprotinin
for 15 min at room temperature. Detergent-treated cells were
washed twice in the absence of NP-40 and subjected to
DNase treatment (20 U/ml for 15 min at room temperature).
Samples were fixed with 4% paraformaldehyde and processed
for immunofluorescence labeling.
Antibodies
The antibodies employed for western blot analysis or immuno-
fluorescence labeling were as follow: anti-lamin A/C, mono-
clonal (Novocastra Laboratories, NCL-LAM-A/C); anti-lamin
A/C, goat polyclonal, (Santa Cruz, sc-6215); anti-pre-lamin
A, goat polyclonal (Santa Cruz, sc-6214) (15); anti-SREBP1,
rabbit polyclonal (Santa Cruz, sc-8984); anti-emerin, mouse
monoclonal (Novocastra Laboratories, NCL-emerin); anti-
PPARg, mouse monoclonal (Santa Cruz, sc-7273); anti-actin,
goat polyclonal (Santa Cruz, sc-1616) and anti-FLAG, rabbit
polyclonal (Sigma, F-7425).
Western blot and immunoprecipitation
Western blot analysis of cellular lysates from human fibrobasts
and 3T3-L1 pre-adipocytes was done as follows. Cells were
lysed in buffer containing 1% NP-40, 0.25% sodium deoxy-
cholate, 150 mM NaCl, 1 mM EGTA, 1 mM PMSF, 1 mM
NaF, 1 mM aprotinin, leupeptin and pepstatin. Proteins were
loaded in Laemmli sample buffer and subjected to SDS–
PAGE followed by immunochemical reactions. For immuno-
precipitation analysis, human fibroblasts and 3T3-L1 pre-
adipocytes were treated with a buffer containing 50 mM
HEPES–HCl pH 7.4, 100 mM NaCl, 1% NP-40, 1 mM
PMSF, 1 mM dithiothreitol, 1.5 mM MgCl2, 10 mM of each
leupeptin, pepstatin, aprotinin for 10 min at 48C. After soni-
cation, cell extracts were clarified by 12 000g centrifugation
at 48C. Protein A/G–Sepharose beads were incubated with
anti-SREBP1 or with anti-pre-lamin A antibodies for 14 h at
48C and unbound antibodies were removed by centrifugation.
Cellular extracts were incubated with antibody-coupled
Sepharose beads for 3 h at 48C. Immunoprecipitated com-
plexes were diluted in Laemmli buffer, subjected to SDS–
PAGE (6–20%) and transferred to nitrocellulose membrane.
Membranes were saturated with 5% dried skimmed milk–
4% bovine serum albumin (BSA) and incubation with
primary antibodies was performed for 1 h at room tempera-
ture. Immunoblotted bands were revealed by the Amersham
ECL detection system. Densitometry of immunoblotted
bands was performed by a Biorad GS-800 calibrated densi-
tometer. Statistical analysis was performed by Student’s t-test.
Immunofluorescence
Human fibroblasts and 3T3-L1 pre-adipocytes grown on cov-
erslips were fixed in methanol at 208C. In situ DNase extracted
samples were fixed by 4% paraformaldehyde. Samples
were incubated with PBS containing 4% BSA to saturate
non-specific binding. Primary antibodies were applied over-
night at 48C, secondary antibodies were applied for 1 h at
room temperature. Slides were mounted with an anti-fade
reagent in glycerol and observed with a Nikon E 600 fluor-
escence microscope equipped with a digital camera. Pictures
were elaborated with Photoshop-6 software.
Oil red O staining
Oil red O staining of cultured 3T3-L1 pre-adipocytes was per-
formed to stain lipid droplets. Cells were fixed for 1 h at room
temperature with 10% formalin in isotonic buffer, washed
three times with distilled water, and then stained with 0.6%
(wt/vol) oil red O solution (60% isopropanol, 40% water)
for 1 h at 228C. After washing three times with distilled
water, the cells were examined under a microscope (16).
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